Echocardiographic Diagnosis and Prognosis of Fetal Left Ventricular Noncompaction

Lucile Packard Children's Hospital, Stanford University Medical Center, Division of Pediatric Cardiology, Palo Alto, California 94304, USA.
Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography (Impact Factor: 3.99). 01/2012; 25(1):112-20. DOI: 10.1016/j.echo.2011.09.019
Source: PubMed

ABSTRACT Left ventricular noncompaction (LVNC) has rarely been described in the fetus.
The presence of associated congenital heart disease and rhythm disturbance was identified and the presence of heart failure was assessed using the cardiovascular profile score in all fetuses with LVNC presenting from January 1999 to July 2010. The left ventricle was divided into 12 segments-four segments each at the base, midpapillary, and apical regions-in the short-axis view to calculate the noncompaction/compaction ratio for each segment.
Of 24 fetuses with LVNC included in the study, 22 had significant congenital heart disease, and 15 had complete heart block. Of the 16 patients with adequate follow-up and not electively terminated, 12 (81%) died or progressed to heart transplantation. The average noncompaction/compaction ratios were 2.02 in patients who died or underwent heart transplantation and 1.67 in survivors (P = .2034). Fifty-seven of 93 measured segments (61%) of the left ventricle in the patients who died or underwent heart transplantation had noncompaction/compaction ratios ≥ 2 compared with five of 17 measured segments (29%) in survivors (P = .0837). The average cardiovascular profile score was 6. The apical region had greater involvement of noncompaction than the midpapillary and basal regions, with ratios of 2.27, 2.14, and 1.10, respectively (P = .00035).
Fetuses with LVNC have a poor prognosis that may be related to associated congenital heart disease, increased segmental involvement of noncompaction, and complete heart block and can be predicted by the cardiovascular profile score.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Whether left ventricular noncompaction (LVNC) is a distinct cardiomyopathy or a morphologic trait shared by different cardiomyopathies remains controversial. Current guidelines from professional organizations recommend different strategies for diagnosing and treating patients with LVNC. This state-of-the-art review discusses new insights into the basic mechanisms leading to LVNC, its clinical manifestations, treatment modalities, anatomy and pathology, embryology, genetics, epidemiology, and imaging. Three markers currently define LVNC: prominent left ventricular trabeculae, deep intertrabecular recesses, and a thin compacted layer. Although new genetic data from mice and humans supports LVNC as a distinct cardiomyopathy, evidence for LVNC as a shared morphological trait is not ruled out. Criteria supporting LVNC as a shared morphological trait may depend on consensus guidelines from the multiple professional organizations. Enhanced imaging and increased use of genetics are both predicted to significantly impact our overall understanding of the basic mechanisms causing LVNC and its optimal management.
    Journal of the American College of Cardiology 10/2014; 64(17):1840–1850. DOI:10.1016/j.jacc.2014.08.030 · 15.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To evaluate the prenatal diagnosis of ventricular non-compaction cardiomyopathy (NCCM) and to report the pathologic features and the characteristic myocardial ultrastructure of fetal NCCM.Method We examined 9 cases of fetal NCCM by prenatal echocardiography from 2004 to 2013. These cases were evaluated with respect to prenatal diagnosis, outcomes, pathology and characteristics of the myocardial ultrastructure.ResultsTrabeculated myocardium and non-compaction/compaction ratio (N/C ratio) ≥2.0 is the echocardiographic feature that allowed diagnosis. Among the 9 fetuses with a prenatal diagnosis of NCCM, 6 were diagnosed with left ventricular non-compaction (LVNC), 2 with non-compaction of both ventricles (biventricular NCCM), and 1 with right ventricular non-compaction (RVNC). Among the 9 fetuses, the LVNC diagnosis was confirmed by postnatal echocardiography in 2; the other patients chose to terminate their pregnancies, and those cases were confirmed at autopsy. Muscle biopsies were performed on 3 of the aborted fetuses, and abnormal mitochondria, sarcomeres and myocardial fibers were observed.Conclusion Non-compaction can be identified in the fetus. Fetal non-compaction most often involves the LV, but can involve the RV or both ventricles. The myocardial ultrastructure of fetal ventricular non-compaction has certain unique characteristics regarding the maturation of the mitochondria, sarcomeres and myocardial fibers. This article is protected by copyright. All rights reserved.
    Prenatal Diagnosis 10/2014; 35(3). DOI:10.1002/pd.4523 · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective With the help of fetal echocardiography, cardiovascular profile score (CVPS) can be evaluated. However, no general agreement has been recognized on the prediction value of CVPS on fetal adverse outcome. Methods Literature review has identified up to Nov, 2012 in the databases. Meta-analysis was performed in a fixed/random-effect model using Revman 5.1.1 and Meta-disc 1.4. The differences among different cut-offs were measured by STATA 11.0. Results Result from 7 studies reported an outcome in favor of significant lower CVPS in fetus of adverse outcome with Std. Mean Difference of -1.17 (95% CI=-1.78, -0.55). The overall performance of CVPS≤6 prediction adverse outcome evaluated as area under the summary receiver operating characteristic curves (AUC) was 0.8777. The AUC of CVPS≤7 was 0.8728 and the AUC of CVPS≤8 was 0.7207. However, the result indicated the performance of CVPS≤6 prediction adverse outcome had a statistical significance comparing to other 2 cut-offs. Conclusion Analysis has proven the CVPS is a credible index for predicting fetal adverse outcome. And once CVPS decreased at 8, the patient should be observed carefully. With the CVPS dropped at 7, treatment is demanded immediately while some cases suffer irreversible cardiac dysfunction.
    Journal of Maternal-Fetal and Neonatal Medicine 10/2014; DOI:10.3109/14767058.2014.974536 · 1.21 Impact Factor